Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02115243
Title Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Duke University
Age Groups: adult
Covered Countries USA

No variant requirements are available.